FDA approves Eli Lilly's oral GLP-1 Foundayo for weight loss

The FDA has approved Foundayo (orforglipron) for long-term weight reduction, giving Eli Lilly an oral GLP-1 to sell alongside its injectable obesity medicines and setting up a direct contest with Novo Nordisk's oral Wegovy ^[1][2]. The agency's list of novel drug approvals for 2026 gives Foundayo an approval date of April 1, 2026 ^[1].

The approved use covers adults with obesity, or adults with overweight who also have at least one weight-related condition, in combination with a reduced-calorie diet and increased physical activity ^[1]. Orforglipron is a non-peptide GLP-1, which sets it apart from semaglutide, the molecule in Novo Nordisk's Wegovy pill ^[2]. Novo sells semaglutide as a pill and as the original injectable under the same brand ^[2].

Prescription tracking shows the Wegovy pill, launched in January, remains far ahead. In the week covered by the tracker's Sept. 11, 2026 update, the Wegovy pill recorded about 183,000 total prescriptions, up from roughly 181,000 the week before, while Foundayo rose nearly 8% to 47,500 ^[2]. The figures come from IQVIA data cited by analysts at Citi, who cautioned that IQVIA may still be missing some Foundayo prescriptions filled through telehealth ^[2]. A separate Jefferies note described in the same tracker put Foundayo's share of new prescriptions, which exclude refills, at 21.5% of the oral obesity market in late August ^[2].

Foundayo's early pace has trailed the Wegovy pill's. When Foundayo passed 40,000 weekly prescriptions in late August, in its 20th week on the market, the number was well below the roughly 57,000 prescriptions the Wegovy pill recorded in week six of its launch ^[2]. Lilly reported $98 million in Foundayo sales for the second quarter, including $67 million in the U.S., a result the tracker said disappointed many observers ^[2]. CEO David Ricks said on an earnings call that Lilly began broad direct-to-consumer marketing after securing commercial access across the three major pharmacy benefit managers in June, and Ilya Yuffa, president of Lilly USA, said the company is "starting to see an inflection point on Foundayo now" ^[2].

Coverage timing differed between the two pills. CVS, the last of the big three pharmacy benefit managers to cover Foundayo, began doing so June 1, while the Wegovy pill had full coverage in its first week on the market, according to Jefferies ^[2]. The Medicare GLP-1 Bridge program, which went live July 1, offers coverage for certain weight-loss medicines, including Foundayo, for a $50 copayment per month ^[2]. Across the class, total GLP-1 prescriptions rose 5.4% over the four weeks ending with the Sept. 11 update, compared with a 6.8% decline a year earlier; Citi analysts attributed the swing to the expansion of oral GLP-1s, which they said is likely broadening access and drawing in new patients ^[2]. Tirzepatide, which Lilly sells as Zepbound for obesity, held nearly 57% of the total GLP-1 market, up from about 49.5% a year earlier, while semaglutide was roughly flat at 37% ^[2].

Why it matters for patients

Adults who prefer a pill to an injection now have two oral GLP-1 options from different manufacturers, and they are not the same drug: Foundayo is orforglipron, and the Wegovy pill is semaglutide ^[1][2]. The tracker frames part of the competition around convenience, noting that Lilly is betting that Foundayo's freedom from strict fasting and water requirements can give it an edge ^[2].

Insurance coverage shapes access as much as prescribing does. The two products reached broad pharmacy benefit manager coverage on different timelines, and the Medicare Bridge program's $50 monthly copayment applies to certain weight-loss medicines including Foundayo ^[2]. The prescription figures reported here are filled prescriptions, not measures of weight loss; no head-to-head weight-loss results from the two launches have been reported ^[2]. Analysts also say the prescription data may undercount Foundayo because telehealth fills are not fully captured ^[2].

What happens next

The tracker is updated weekly with IQVIA prescription counts cited by Citi and Jefferies, so the two pills' trajectories will keep being compared ^[2]. Jefferies analysts modeled about $71 million in U.S. Foundayo sales for the second quarter, below the $130 million Wall Street consensus, while projecting the drug could still reach a consensus revenue estimate of $1.2 billion for 2026 ^[2]. The FDA's 2026 list shows a single approval for Foundayo, and no additional label actions have been reported ^[1].